Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors
- 27 February 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 15 (3), 307-315
- https://doi.org/10.1517/13543784.15.3.307
Abstract
Rimonabant is the first selective blocker of the cannabinoid CB1 receptors being developed for the treatment of obesity, tobacco smoking and cardiometabolic risk factors. Following 1 year of treatment, rimonabant 20 mg/day leads to greater weight loss compared with placebo. Therapy with rimonabant is also associated with favourable changes in serum lipids and an improvement in glycaemic control in Type 2 diabetics. At the same dose, rimonabant significantly increases the cigarette smoking quit rates compared with placebo. Rimonabant appears to be generally well tolerated, with primary side effects of mild nausea, diarrhoea, anxiety and depression. As an agent with a novel mechanism of action, rimonabant has the potential to be a useful adjunct to lifestyle modification in the treatment of obesity, metabolic syndrome and cigarette smoking.Keywords
This publication has 61 references indexed in Scilit:
- The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balanceThe FASEB Journal, 2005
- ObesityCirculation, 2005
- Smoking Cessation and Mortality from Cardiovascular Disease among Japanese Men and Women: The JACC StudyAmerican Journal of Epidemiology, 2005
- Presynaptic cannabinoid CB1 receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed ratsBritish Journal of Pharmacology, 2004
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Primary Prevention of Coronary Heart Disease in Women through Diet and LifestyleNew England Journal of Medicine, 2000
- The endothelial component of cannabinoid‐induced relaxation in rabbit mesenteric artery depends on gap junctional communicationThe Journal of Physiology, 1999
- Two‐Year Changes in L ipids and Lipoproteins Associated with the Maintenance of a 5 % to 10% Reduction in Initial Weight: Some Findings and Some QuestionsObesity Research, 1999
- The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric arteryBritish Journal of Pharmacology, 1998
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorFEBS Letters, 1994